Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Selective Histone Deacetylase 6 Inhibitors Bearing Substituted Urea Linkers Inhibit Melanoma Cell Growth
Joel Bergman, Karrune Woan, Patricio Perez-Villarroel, et al.
Journal of Medicinal Chemistry (2012) Vol. 55, Iss. 22, pp. 9891-9899
Open Access | Times Cited: 181

Showing 1-25 of 181 citing articles:

HDACs and HDAC Inhibitors in Cancer Development and Therapy
Yixuan Li, Edward Seto
Cold Spring Harbor Perspectives in Medicine (2016) Vol. 6, Iss. 10, pp. a026831-a026831
Open Access | Times Cited: 1036
Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials
Ann Lin, Christopher J. Giuliano, Ann Palladino, et al.
Science Translational Medicine (2019) Vol. 11, Iss. 509
Open Access | Times Cited: 593
Histone deacetylase 6 in cancer
Ting Li, Chao Zhang, Shafat Hassan, et al.
Journal of Hematology & Oncology (2018) Vol. 11, Iss. 1
Open Access | Times Cited: 277
Urea Derivatives in Modern Drug Discovery and Medicinal Chemistry
Arun K. Ghosh, Margherita Brindisi
Journal of Medicinal Chemistry (2019) Vol. 63, Iss. 6, pp. 2751-2788
Open Access | Times Cited: 261
Structural insights into HDAC6 tubulin deacetylation and its selective inhibition
Y. Miyake, J.J. Keusch, Longlong Wang, et al.
Nature Chemical Biology (2016) Vol. 12, Iss. 9, pp. 748-754
Closed Access | Times Cited: 255
Histone Deacetylase 6 in Health and Disease
Carole Seidel, Michaël Schnekenburger, Mario Dicato, et al.
Epigenomics (2015) Vol. 7, Iss. 1, pp. 103-118
Closed Access | Times Cited: 196
Augmenting Antitumor Immune Responses with Epigenetic Modifying Agents
Erika Héninger, Timothy Krueger, Joshua M. Lang
Frontiers in Immunology (2015) Vol. 6
Open Access | Times Cited: 184
HDAC6 as privileged target in drug discovery: A perspective
Sravani Pulya, Sk. Abdul Amin, Nilanjan Adhikari, et al.
Pharmacological Research (2020) Vol. 163, pp. 105274-105274
Closed Access | Times Cited: 179
Development of Multifunctional Histone Deacetylase 6 Degraders with Potent Antimyeloma Activity
Hao Wu, Ka Yang, Zhongrui Zhang, et al.
Journal of Medicinal Chemistry (2019) Vol. 62, Iss. 15, pp. 7042-7057
Closed Access | Times Cited: 149
A Review of Progress in Histone Deacetylase 6 Inhibitors Research: Structural Specificity and Functional Diversity
Xin-Hui Zhang, Qin-Ma, Hui-Pan Wu, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 3, pp. 1362-1391
Closed Access | Times Cited: 106
Targeting histone deacetylases for cancer therapy: Trends and challenges
Liang Tao, Fengli Wang, Reham M. Elhassan, et al.
Acta Pharmaceutica Sinica B (2023) Vol. 13, Iss. 6, pp. 2425-2463
Open Access | Times Cited: 82
Target deconvolution of HDAC pharmacopoeia reveals MBLAC2 as common off-target
Severin Lechner, Martin Ian P. Malgapo, Christian Grätz, et al.
Nature Chemical Biology (2022) Vol. 18, Iss. 8, pp. 812-820
Open Access | Times Cited: 72
Unusual zinc-binding mode of HDAC6-selective hydroxamate inhibitors
N.J. Porter, Adaickapillai Mahendran, Ronald Breslow, et al.
Proceedings of the National Academy of Sciences (2017) Vol. 114, Iss. 51, pp. 13459-13464
Open Access | Times Cited: 150
Recent advances in the discovery of potent and selective HDAC6 inhibitors
Xiuxiu Wang, Renzhong Wan, Zhao‐Peng Liu
European Journal of Medicinal Chemistry (2017) Vol. 143, pp. 1406-1418
Closed Access | Times Cited: 136
Development of a histone deacetylase 6 inhibitor and its biological effects
Ju‐Hee Lee, Adaickapillai Mahendran, Yuanshan Yao, et al.
Proceedings of the National Academy of Sciences (2013) Vol. 110, Iss. 39, pp. 15704-15709
Open Access | Times Cited: 132
Targeting histone deacetylase 6 mediates a dual anti‐melanoma effect: Enhanced antitumor immunity and impaired cell proliferation
Karrune Woan, Maritza Lienlaf, P. Perez-Villaroel, et al.
Molecular Oncology (2015) Vol. 9, Iss. 7, pp. 1447-1457
Open Access | Times Cited: 128
Drugging the HDAC6–HSP90 interplay in malignant cells
Oliver H. Krämer, Siavosh Mahboobi, Andreas Sellmer
Trends in Pharmacological Sciences (2014) Vol. 35, Iss. 10, pp. 501-509
Open Access | Times Cited: 123
Trend of Histone Deacetylase Inhibitors in Cancer Therapy: Isoform Selectivity or Multitargeted Strategy
Lei Zhang, Yantao Han, Qixiao Jiang, et al.
Medicinal Research Reviews (2014) Vol. 35, Iss. 1, pp. 63-84
Closed Access | Times Cited: 121
Development and Therapeutic Implications of Selective Histone Deacetylase 6 Inhibitors
Jay H. Kalin, Joel Bergman
Journal of Medicinal Chemistry (2013) Vol. 56, Iss. 16, pp. 6297-6313
Closed Access | Times Cited: 120
The Search for Potent, Small‐Molecule HDACIs in Cancer Treatment: A Decade After Vorinostat
Chiara Zagni, Giuseppe Floresta, Giulia Monciino, et al.
Medicinal Research Reviews (2017) Vol. 37, Iss. 6, pp. 1373-1428
Closed Access | Times Cited: 117
Next-generation of selective histone deacetylase inhibitors
Feifei Yang, Na Zhao, Di Ge, et al.
RSC Advances (2019) Vol. 9, Iss. 34, pp. 19571-19583
Open Access | Times Cited: 112
Recent Progress in Histone Deacetylase Inhibitors as Anticancer Agents
Loredana Cappellacci, Diego Romano Perinelli, Filippo Maggi, et al.
Current Medicinal Chemistry (2018) Vol. 27, Iss. 15, pp. 2449-2493
Closed Access | Times Cited: 111
Developing potent PROTACs tools for selective degradation of HDAC6 protein
Zixuan An, Wenxing Lv, Shang Su, et al.
Protein & Cell (2019) Vol. 10, Iss. 8, pp. 606-609
Open Access | Times Cited: 111
Synthesis and Biological Investigation of Oxazole Hydroxamates as Highly Selective Histone Deacetylase 6 (HDAC6) Inhibitors
Johanna Senger, Jelena Melesina, Martin Marek, et al.
Journal of Medicinal Chemistry (2015) Vol. 59, Iss. 4, pp. 1545-1555
Closed Access | Times Cited: 104
mTOR and HDAC Inhibitors Converge on the TXNIP/Thioredoxin Pathway to Cause Catastrophic Oxidative Stress and Regression of RAS-Driven Tumors
Clare F. Malone, Chloe E. Emerson, Rachel Ingraham, et al.
Cancer Discovery (2017) Vol. 7, Iss. 12, pp. 1450-1463
Open Access | Times Cited: 103
Page 1 - Next Page

Scroll to top